Table 3 Factors associated with overall survival and progression-free survival

Gender

 Female vs male

0.927

0.154–5.563

0.934

0.424

0.103–1.739

0.234

ECOG

 0 vs 1

5.497

0.542–66.801

0.150

0.873

0.217–3.511

0.849

Histopathology

 Adenocarcinoma vs SCC

0.087

0.005–1.393

0.084

0.232

0.024–2.250

0.208

Genetic mutation

 EGFR vs ALK

0.580

0.015–39.800

0.277

2.003

0.243–260.278

0.657

Clinical stage

 III vs IV

0.853

0.152–4.794

0.857

1.632

0.437–6.095

0.466

Preoperative stage

 I/II vs III

3.205

0.582–17.663

0.181

4.377

1.083–17.691

0.038

ypStage

 I/II/III vs IV

0.207

0.018–2.320

0.202

0.221

0.062–1.900

0.344

Indication for TKI

 Neoadjuvant vs treatment

0.375

0.043–3.287

0.376

1.184

0.294–4.764

0.812

Indication for surgery

 Regressed vs regrowth

0.086

0.008–0.957

0.046

0.299

0.054–1.652

0.166

Surgery

 Lobectomy vs sublobectomy

0.348

0.031–3.853

0.289

0.904

0.179–4.566

0.903

Completeness resection

 R0 vs R2

4.828

0.431–54.077

0.202

2.911

0.526–16.100

0.221

Postoperative TKI adjuvant

 Yes vs no

0.506

0.099–2.587

0.413

0.146

0.027–0.782

0.025

Relapse

 Yes vs no

6.268

0.701–825.479

0.259